Vivera Pharmaceuticals Partners With Areum Bio LLC and Access Bio, Inc. To Expand The National Distribution Of Emergency Use Authorized COVID-19 Rapid Tests

Vivera Pharmaceuticals, Inc. and diagnostic testing distributor, Areum Bio LLC, announce their channel partnership to expand the distribution of Access Bio, Inc.’s CareStart™ COVID-19 Rapid Antigen Test and line of products granted FDA Emergency Use Authorization (EUA). Areum Bio is already a major distributor of New Jersey manufacturer, Access Bio’s CareStart™ COVID-19 Rapid Antigen Test, and will seek to bolster supply chain efforts through Vivera’s extensive network of health care providers and organizations.

Recommended AI News: C***** Group Partners With Accenture And Google Cloud To Accelerate Its Digital Strategy

As universities, businesses, airlines, and public venues integrate routine testing as a part of their return to school, work, travel, and gathering protocols, the availability of reliable COVID-19 testing remains a key necessity. The efficiency of the EUA-authorized point of care (POC) CareStart™ Rapid Antigen Test, coupled with Vivera’s broad distribution capabilities, will ensure the greater ease of access to rapid diagnostic testing solutions.

By expanding access to testing, Vivera will ensure that measurable outcomes are achievable for our partners and patients

The U.S. has achieved major milestones in overcoming the height of the pandemic, but with lower than ideal vaccination rates and the ongoing threat of emerging variants worldwide, it remains critical that the nation continues to follow COVID-19 testing protocols to reduce viral spread. The distribution partnership between Vivera, Areum Bio, and Access Bio will help make rapid testing more readily available as quickly as possible. As an authorized distributor of the CareStart™ Rapid Antigen Test, Vivera intends to expand its outreach to ensure health care providers and patients are able to access rapid testing to help keep our communities safe.

Recommended AI News: SonyLIV Enters Into Strategic Partnership With TCS to Transform Customer Experience and Drive Growth

“This co-branded collaboration marks a new strategic alliance for Vivera,” said Paul Edalat, Chairman and CEO of Vivera Pharmaceuticals. “The Company is proud to partner with Areum Bio and Access Bio to provide the health care organizations and patients we serve nationwide with a fast and reliable EUA-authorized COVID-19 test. By expanding access to testing, Vivera will ensure that measurable outcomes are achievable for our partners and patients and especially for the vulnerable communities that rely on us most.”

“This is a great opportunity for Areum Bio to partner with Vivera, a reputable pharmaceutical company, for the nationwide distribution of the CareStart™ COVID-19 Rapid Antigen Tests,” said Dr. Jong Kim, President of Areum Bio. “Utilizing our shared passion and areas of expertise through this partnership, we will be able to deliver rapid and reliable test kits to communities nationwide in a more timely and efficient manner. We believe that even the most innovative medical devices are of no value unless they are dispensed to the patients who need them. At Areum Bio, it is our firm belief that we only succeed when our innovative devices reach the patients and providers and serve their purposes. For this reason, we always work diligently to deliver our products to our customers in a quick, effective manner.”

Through their strategic distribution partnership, Vivera, Areum Bio, and Access Bio hope to support the nation’s safe and seamless return to normality by contributing to the increased availability of high-quality rapid testing across the country.

Recommended AI News: Silicon Mobility with Cascadia Motion show up to 4.6% motor and inverter efficiency improvements by…